Latest From Dexcom Inc.
Market Brief: Abbott, Dexcom Help Drive Continuous Glucose Monitoring Market; 30% Expected Growth by 2023
Global sales of blood glucose monitoring devices are expected to reach $13bn by 2023, a CAGR of nearly 11%, led by the rising adoption of continuous glucose monitoring systems (CGMs). Abbott and Dexcom have been major drivers in the CGM market, but competition is fierce.
Tandem Diabetes Care received FDA clearance for its Control-IQ technology for use with Tandem's t:slim X2 insulin pump and Dexcom's G6 continuous glucose monitoring system, making it the first hybrid closed-loop system to deliver automatic correction boluses and adjust background insulin levels to help prevent high and low blood sugars.
Market Intel: Bigfoot Biomedical, Beta Bionics Getting Pumped To Introduce Next-Gen Artificial Pancreas
The insulin pump market, which is dominated by four major players, is facing rising competition from smaller, innovative companies. This second part of a two-part series focuses on five emerging companies: Beta Bionics, Bigfoot Biomedical, Diabeloop, EOFlow and Ypsomed.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
In Vitro Diagnostics
- Glucose Testing
- Monitoring Equipment & Devices
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- Dexcom Inc.
- Senior Management
Kevin Sayer, Pres. & CEO
Quentin Blackford, CFO & COO
Richard B Doubleday, Chief Commercial Officer
Jacob Leach, CTO
Steven Pacelli, EVP, Strategy & Corp. Dev.
- Contact Info
Phone: (858) 200-0200
6340 Sequence Dr.
San Diego, CA 92121
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.